AzTrials
AzTrials

Liver FailureNCT04139473

Randomized Trial of Hepaticojejunostomy Versus Duct-to-duct Anastomosis in Right Lobe Living Donor Liver Transplantation

A study testing Hepaticojejunostomy / Duct-to-duct anastomosis in people with Liver Failure, run by The University of Hong Kong at 2 sites in Hong Kong.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The scarcity of deceased donor organ supply has driven the practice of living donor liver transplantation (LDLT). Right lobe LDLT (RLDLT) has developed over the last 10 years to extend the benefit of LDLT to adult patients. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Liver Failure
What is being tested?
Hepaticojejunostomy / Duct-to-duct anastomosis
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
200 participants
Where
2 sitesHong Kong
Study dates
15 May 2012to 31 Dec 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • recipient age older than 18 years
  • primary transplant

Who cannot join

  • recipient refusal/withdrawal
  • haemodynamic instability at the time of biliary reconstruction
  • biliary reconstruction with duct-to-duct anastomosis is unsafe or technically not feasible
  • unhealthy recipient's bile duct, anatomical variant in donor's right duct
  • biliary reconstruction with hepaticojejunostomy is unsafe or technically not feasible
  • excessively edematous bowel, failure to create Roux-en-Y jejunal loop due to excessive
  • bowel adhesions

Trial locations and contacts

2 sites in 1 country.

Hong Kong2 sites, 2 recruiting
  • Queen Mary Hospital

    Hong Kong

    Kenneth Chok, MBBS, 085222553025 ext. 085222553025, chok6275@hku.hk

    Recruiting
  • Queen Mary Hospital

    Hong Kong

    Recruiting

Other trials in Hong Kong

About this study

The scarcity of deceased donor organ supply has driven the practice of living donor liver transplantation (LDLT). Right lobe LDLT (RLDLT) has developed over the last 10 years to extend the benefit of LDLT to adult patients. With technical refinement, the results have significantly improved but bile duct complications remain the Achilles heel that affects the recipient's long-term outcome.Hepaticojejunostomy (HJ) was originally the standard technique for bile duct reconstruction in RLDLT but in recent years, duct-to-duct anastomosis (DDA) has been adopted by most transplant centers. The advantages of duct-to-duct reconstruction include a shorter operation time, less infection complications, more physiologic enteric functions and easier endoscopic access to the biliary tract but bile duct complication, particularly stricture is the major concern. The development of stricture is likely to be related to the blood supply of the anastomosis. We hypothesize that HJ has a better blood supply and is associated with a lower overall bile duct complication rate than duct-to-duct anastomosis. We propose a randomized trial to test this hypothesis and to compare various outcome measures between HJ and duct-to-duct reconstruction. The results of the study will set the standard for the technique of biliary reconstruction in RLDLT and will further advance this procedure.

Read the detailed description

Liver transplantation is a life-saving procedure for patients with end-stage liver disease. The demand for the operation, however, always exceeds the supply from deceased organ donors and living donor liver transplant (LDLT) has been developed to provide an alternative option. LDLT was initially limited to paediatric recipients because of the restriction imposed by the graft size. In order to extend the benefit of LDLT to adult recipients, we proposed the use of a right lobe liver graft from a living donor and performed the first RLDLT for an adult recipient on May 9, 1996. Following the report of our first series of 8 cases in 1997, RLDLT has developed rapidly and has been adopted by many transplant programs around the world. LDLT has the most significant impact in Asia where the issue of organ shortage is most extreme. The availability of RLDLT for adult recipients provides the driving force for a drastic increase in LDLT in recent years. Our recent survey (unpublished data) indicated that the number of LDLT performed in Asia each year has increased by 9 folds since the introduction of RLDLT 10 years ago and is continuously rising. In the year 2005, LDLT accounts for 90% of the 1497 liver transplants performed in Asia (excluding mainland China). In Hong Kong, over two-thirds of the liver transplants are from living donors and the majority (90%) are RLDLT performed for adult recipients. RLDLT involved one of the most complicated and technically demanding surgical procedure. When our first series was reported in 1997, there was a high morbidity and reoperation rate in the recipients. Since then, various advances in technique and management have been introduced, including a better understanding of the minimum graft size requirement and anatomic variants of the right lobe, improved selection criteria for donors and recipients, as well as technical modifications; particularly in venous outflow and biliary reconstruction. There is a learning curve in RLDLT and through the lessons learnt in our first 100 RLDLT, we have dramatically improved the outcome of both the donors and recipients and an excellent graft survival rate of over 90% could be achieved even in high-risk recipients. The major technical hurdle that remains is biliary complication which affects the long-term outcome and quality of life and is occasionally the cause of graft loss and patient death. Hepaticojejunostomy was the standard technique for biliary reconstruction in RLDLT. The reported incidence of biliary complications in early reported retrospective series was high, ranging from 15 to 64%. Wach et al. first reported the technique of duct-to-duct reconstruction for RLDLT in 1998. Biliary stricture developed four weeks later and the anastomosis was subsequently revised to a Roux-e-Y HJ. Nonetheless, duct-to-duct reconstruction has the potential advantages of a shorter operation time, less septic complications, more physiologic enteric functions and easier endoscopic access to the biliary tract and these seem so obvious that duct-to-duct anastomsis has become the preferred technique in many transplant centers. In a retrospective study of 259 adult LDLTs; including 225 RLDLT from the Asan Medical Center in South Korea, Shin Hwang et al. reported an increasing preference for duct-to-duct anastomosis over HJ, with duct-to-duct anastomosis comprising 29.9% of the procedures in 2000 increasing to 69.3% in 2001 and 83.7% in 2002. The 3-year cumulative biliary complication rate, however, increased progressively form 13.7% in 2000 to 15.8% in 2001 and 25.4% in 2002. This rising incidence of biliary complication contrasted sharply with the improving results in other outcome measures of RLDLT which has been attributed to the learning curve effect. The authors demonstrated that for a right lobe graft with a single biliary reconstruction, a graft duct size less than 4 mm in diameter was a risk factor for biliary stricture in duct-to-duct anastomosis but not for HJ. They suggested that duct-to-duct anastomosis had inherent deficiencies that could not be overcome by current surgical techniques and recommended HJ as the preferred approach under such circumstances.We performed a retrospective study at our centre, in 265 RLDLT recipients, 55 (20.8%) developed postoperative BAS. The BAS rates were 21.4% (43/201) for recipients undergoing duct-to-duct anastomosis during transplantation, 18.9% (10/53) for recipients undergoing HJ, and 18.2% (2/11) for recipients undergoing both procedures. BAS and non-BAS patients had comparable demographics. The number of graft bile duct openings (P = 0.516) and the size of the graft's smallest bile duct (5 versus 5 mm, P = 0.4) were not significantly different between BAS and non-BAS patients. Univariate analysis showed that the factors associated with postoperative BAS were the recipient warm ischemia time (55 versus 51 minutes, P = 0.026), graft cold ischemia time (120 versus 108 minutes, P = 0.046), stent use (21.8% versus 7.1%, P = 0.001), postoperative acute cellular rejection (29.1% versus 11.0%, P = 0.001), and University of Wisconsin solution use (21.8% versus 7.1%, P = 0.001). Multivariate analysis showed that the cold ischemia time (odds ratio = 1.012, 95% confidence interval = 1.002-1.023, P = 0.014) and acute rejection (odds ratio = 3.180, 95% confidence interval = 1.606-6.853, P = 0.002) were significant factors. The graft survival rates of BAS and non-BAS patients were comparable. One patient required retransplantation for secondary biliary cirrhosis. In conclusion, BAS remains common after adult RLDLT regardless of DDA or HJ. The graft cold ischemia time and postoperative acute cellular rejection are significantly associated with postoperative BAS. A randomised controlled trial is definitely needed to see which methoid is superior to another. Since we reported the first series of RLDLT in 1997, we have introduced numerous technical refinements; particularly in venous outflow and biliary reconstruction. HJ was originally the standard technique and technical modifications were directed at preserving the blood supply to the graft right hepatic duct during the donor operation. A retrospective study on the first 74 right lobe transplants showed that the biliary complication rate has decreased significantly from 43% in the first 37 patients to 8% only in the second 37 patients. In particular, there was no biliary leakge in the second group of patients. Since then, however, we have switched from HJ to duct-to-duct anastomosis as the preferred technique for biliary reconstruction because of its apparently obvious advantages. With the new technique, however, three of 41 patients (7%) had biliary leakage and 10 (24%) developed biliary stricture at a median of 5.8 months (range 1.5 to 16.9 months) after transplant. These results were comparable to those of the Kyoto group in which the incidence of bile leakage was 10% and that of stricture 23%. A randomized trial is the only way to objectively determine whether HJ or duct-to-duct anastomosis should be the preferred technique for biliary reconstruction in RLDLT. Since the results of biliary reconstruction is highly dependent on the technique of the surgical team, a multi-center study would introduce a serious surgeons' variable that may compromise the interpretation of the results. Hence a randomized trial in a single high volume center using a standard technique by a single surgical team would be the best approach.

Conditions
Liver Failure
Being tested
Hepaticojejunostomy / Duct-to-duct anastomosis
Medical subject headings
Liver Failure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Hepaticojejunostomy / Duct-to-duct anastomosisProcedure or surgery

Study groups in NCT04139473
Study groupRoleWhat they receive
HepaticojejunostomyActive comparatorPatients undergo right lobe living donor liver transplantation will receive hepaticojejunostomy
Receives: Procedure: Hepaticojejunostomy / Duct-to-duct anastomosis
Duct-to-duct anastomosisActive comparatorPatients undergo right lobe living donor liver transplantation will receive duct-to-duct anastomosis
Receives: Procedure: Hepaticojejunostomy / Duct-to-duct anastomosis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Biliary complications

    Compare all biliary-associated complications after operation including leakage and stricture

    Measured: 5 years

Secondary outcomes (4)
  1. Operative time for liver transplantation

    Duration of operative time

    Measured: intraoperative

  2. Gastrointestinal function after liver transplantation

    Return of gastrointestinal function

    Measured: 5 years

  3. Hospital stay after liver transplantation

    Duration of hospital stay

    Measured: 5 years

  4. Chances of re-intervention

    Re-intervention rate

    Measured: 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Oct 2019
  2. Study start15 May 2012
  3. Primary completion31 Dec 2022 (estimated)
  4. Study completion31 Dec 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04139473
Sponsor's protocol ID
UW 12-070
Status last verified
Oct 2019
First submitted
9 Oct 2019
Last updated
25 Oct 2019
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Lo CM, Fan ST, Liu CL, Lo RJ, Lau GK, Wei WI, Li JH, Ng IO, Wong J. Extending the limit on the size of adult recipient in living donor liver transplantation using extended right lobe graft. Transplantation. 1997 May 27;63(10):1524-8. doi: 10.1097/00007890-199705270-00027.

    PubMed 9175822
  • Lo CM, Fan ST, Liu CL, Wei WI, Lo RJ, Lai CL, Chan JK, Ng IO, Fung A, Wong J. Adult-to-adult living donor liver transplantation using extended right lobe grafts. Ann Surg. 1997 Sep;226(3):261-9; discussion 269-70. doi: 10.1097/00000658-199709000-00005.

    PubMed 9339932
  • Wachs ME, Bak TE, Karrer FM, Everson GT, Shrestha R, Trouillot TE, Mandell MS, Steinberg TG, Kam I. Adult living donor liver transplantation using a right hepatic lobe. Transplantation. 1998 Nov 27;66(10):1313-6. doi: 10.1097/00007890-199811270-00008.

    PubMed 9846514
  • Marcos A, Fisher RA, Ham JM, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Posner MP. Right lobe living donor liver transplantation. Transplantation. 1999 Sep 27;68(6):798-803. doi: 10.1097/00007890-199909270-00012.

    PubMed 10515380
  • Trotter JF, Wachs M, Everson GT, Kam I. Adult-to-adult transplantation of the right hepatic lobe from a living donor. N Engl J Med. 2002 Apr 4;346(14):1074-82. doi: 10.1056/NEJMra011629. No abstract available.

    PubMed 11932476
  • Malago M, Testa G, Frilling A, Nadalin S, Valentin-Gamazo C, Paul A, Lang H, Treichel U, Cicinnati V, Gerken G, Broelsch CE. Right living donor liver transplantation: an option for adult patients: single institution experience with 74 patients. Ann Surg. 2003 Dec;238(6):853-62; discussion 862-3. doi: 10.1097/01.sla.0000098619.71694.74.

    PubMed 14631222
  • Todo S, Furukawa H, Jin MB, Shimamura T. Living donor liver transplantation in adults: outcome in Japan. Liver Transpl. 2000 Nov;6(6 Suppl 2):S66-72. doi: 10.1053/jlts.2000.19009.

    PubMed 11084089
  • Bak T, Wachs M, Trotter J, Everson G, Trouillot T, Kugelmas M, Steinberg T, Kam I. Adult-to-adult living donor liver transplantation using right-lobe grafts: results and lessons learned from a single-center experience. Liver Transpl. 2001 Aug;7(8):680-6. doi: 10.1053/jlts.2001.26509.

    PubMed 11510011
  • Lee SG, Park KM, Hwang S, Lee YJ, Kim KH, Ahn CS, Choi DL, Joo SH, Jeon JY, Chu CW, Moon DB, Min PC, Koh KS, Han SH, Park SH, Choi GT, Hwang KS, Lee EJ, Chung YH, Lee YS, Lee HJ, Kim MH, Lee SK, Suh DJ, Kim JJ, Sung KB. Adult-to-adult living donor liver transplantation at the Asan Medical Center, Korea. Asian J Surg. 2002 Oct;25(4):277-84. doi: 10.1016/S1015-9584(09)60192-5.

    PubMed 12470999
  • Nakamura T, Tanaka K, Kiuchi T, Kasahara M, Oike F, Ueda M, Kaihara S, Egawa H, Ozden I, Kobayashi N, Uemoto S. Anatomical variations and surgical strategies in right lobe living donor liver transplantation: lessons from 120 cases. Transplantation. 2002 Jun 27;73(12):1896-903. doi: 10.1097/00007890-200206270-00008.

    PubMed 12131684
  • Olthoff KM, Merion RM, Ghobrial RM, Abecassis MM, Fair JH, Fisher RA, Freise CE, Kam I, Pruett TL, Everhart JE, Hulbert-Shearon TE, Gillespie BW, Emond JC; A2ALL Study Group. Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2ALL Consortium. Ann Surg. 2005 Sep;242(3):314-23, discussion 323-5. doi: 10.1097/01.sla.0000179646.37145.ef.

    PubMed 16135918
  • Lo CM, Fan ST, Liu CL, Chan JK, Lam BK, Lau GK, Wei WI, Wong J. Minimum graft size for successful living donor liver transplantation. Transplantation. 1999 Oct 27;68(8):1112-6. doi: 10.1097/00007890-199910270-00009.

    PubMed 10551638
  • Fan ST, Lo CM, Liu CL. Technical refinement in adult-to-adult living donor liver transplantation using right lobe graft. Ann Surg. 2000 Jan;231(1):126-31. doi: 10.1097/00000658-200001000-00018.

    PubMed 10636112
  • Lo CM, Fan ST, Liu CL, Wong J. Hepatic venoplasty in living-donor liver transplantation using right lobe graft with middle hepatic vein. Transplantation. 2003 Feb 15;75(3):358-60. doi: 10.1097/01.TP.0000046527.19422.3E.

    PubMed 12589159
  • Fan ST, Lo CM, Liu CL, Tso WK, Wong J. Biliary reconstruction and complications of right lobe live donor liver transplantation. Ann Surg. 2002 Nov;236(5):676-83. doi: 10.1097/00000658-200211000-00019.

    PubMed 12409675

Questions about this trial

What is this clinical trial studying?

A study testing Hepaticojejunostomy / Duct-to-duct anastomosis in people with Liver Failure, run by The University of Hong Kong at 2 sites in Hong Kong.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 25 Oct 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Kenneth Chok, MBBS (22553025 ext. 085228592111, chok6275@hku.hk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Biliary complications (time frame: 5 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04139473, which also lists 21 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Oct 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in